Drug delivery strategies for the treatment of malignant gliomas.
As primary brain tumors, malignant gliomas are known to be one of the most insidious types of brain cancer afflicting the humans. The current standard strategy for the treatment of malignant gliomas includes the surgical resection of the tumor when possible, followed by a combination of radiotherapy and/or a certain chemotherapeutic protocol. However, due to the short mean survival, frequent recurrences, and poor prognosis associated with the tumors, new therapeutic strategies are investigated consecutively. These novel drug delivery approaches can be subdivided as systemic and local drug administration. This review focuses on localized drug delivery strategies for the treatment of malignant gliomas, including the injections, infusions, trans-nasal delivery systems, convection enhanced delivery (CED) systems, and various types of polymeric implants. Furthermore, systemic strategies to increase the drug penetration into the brain, such as temporary disruption of the blood brain barrier (BBB), chemical modification of the available therapeutic substances, and utilization of endogenous transport systems will be briefly discussed.
Department of Pharm. Technology, Institute of Pharmacy, University of Bonn, Germany. daniela.allhenn@uni-bonn.de
Daniela
D
Allhenn
Maryam Alsadat Shetab
MA
Boushehri
Alf
A
Lamprecht
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy*; D016503:Drug Delivery Systems; D005910:Glioma / Q000188:drug therapy*; D006801:Humans
D000970:Antineoplastic Agents